Revenue remains highly volatile with quarterly figures fluctuating from zero to $862K, while SG&A expenses consistently exceed $2M, resulting in a negative operating margin of -34.4% in 2026Q1.
| Sales/Revenue | 1.41M | 1.36M | 0 | 0 | 0 | 75K | 30.76K | 0 | 0 | 0 |
| Revenue Growth % | 2148.85% | - | - | - | -100% | 143.82% | - | - | - | - |
| Cost of Goods Sold | 180.63K | 180.63K | 0 | 0 | 0 | 0 | 964.22K | 0 | 0 | 0 |
| COGS % of Revenue | - | 13.25% | - | - | - | - | 3134.54% | - | - | - |
| Gross Profit | 1.23M | 1.18M | 0 | 0 | 0 | 75K | -933.46K | 0 | 0 | 0 |
| Gross Margin % | 87.23% | 86.75% | - | - | - | 100% | -3034.54% | - | - | - |
| Gross Profit Growth % | - | - | - | - | -100% | 108.03% | - | - | - | - |
| Operating Expenses | 14.13M | 14.23M | 10.05M | 21.49M | 34.2M | 14.12M | 5.93M | 0 | 308.31K | 10.08K |
| OpEx % of Revenue | - | 1043.69% | - | - | - | 18827.91% | 19270.98% | - | - | - |
| Selling, General & Admin | 8.86M | 11.95M | 6.72M | 13.82M | 34.18M | 14.12M | 5.78M | 0 | 308.31K | 10.08K |
| SG&A % of Revenue | - | 876.62% | - | - | - | 18827.91% | 18777.71% | - | - | - |
| Research & Development | 1.43M | 1.28M | 2.33M | 6.67M | 20.89K | 0 | 3.54K | 0 | 0 | 0 |
| R&D % of Revenue | - | 93.7% | - | - | - | - | 11.52% | - | - | - |
| Other Operating Expenses | 1.75M | 1M | 1M | 1M | 0 | 0 | 148.19K | 0 | 0 | 0 |
| Operating Income | -12.9M | -13.04M | -10.05M | -21.49M | -34.2M | -14.05M | -6.86M | 0 | -308K | -10.08K |
| Operating Margin % | -912.42% | -956.94% | - | - | - | -18727.91% | -22305.53% | - | - | - |
| Operating Income Growth % | - | -29.73% | 53.22% | 37.15% | -143.46% | -104.71% | - | 100% | -2956.47% | - |
| EBITDA | -11.73M | -11.82M | -9.02M | -20.46M | -33.19M | -13.6M | -6.54M | 171.86K | -344K | 2.65M |
| EBITDA Margin % | -829.87% | -867.24% | - | - | - | -18131.36% | -21254.1% | - | - | - |
| EBITDA Growth % | -16.23% | -31.11% | 55.92% | 38.38% | -144.1% | -107.99% | -3904.24% | 149.96% | -112.99% | - |
| D&A (Non-Cash Add-back) | 1.17M | 1.22M | 1.04M | 1.04M | 1M | 447.41K | 323.43K | 171.86K | -36K | 2.66M |
| EBIT | -12.04M | -11.63M | -10.42M | -21.16M | -37.36M | -13.26M | -9.01M | 0 | -308K | -10.08K |
| Net Interest Income | -459.65K | -525.88K | -396.12K | -107.69K | -218.41K | -187K | -148K | 0 | 0 | 0 |
| Interest Income | 116.5K | 116.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 576.14K | 642.38K | 396.12K | 107.69K | 218.41K | 187.13K | 148.19K | 0 | 0 | 0 |
| Other Income/Expense | 24.01K | 766.31K | -822.92K | 224.59K | -3.38M | 596.65K | -2.29M | -2.23K | 0 | 2.66M |
| Pretax Income | -12.88M | -12.28M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | 0 | 2.65M |
| Pretax Margin % | -910.73% | -900.72% | - | - | - | -17932.37% | -29765.89% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | 0% |
| Net Income | -11.87M | -11.92M | -10.68M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | -344K | 2.65M |
| Net Margin % | -839.69% | -874.29% | - | - | - | -17932.37% | -29765.89% | - | - | - |
| Net Income Growth % | -21.48% | -11.58% | 49.78% | 43.4% | -179.38% | -46.89% | -409760.61% | 99.35% | -112.99% | - |
| Net Income (Continuing) | -12.88M | -12.28M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | -344K | 2.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 401.88K | 506.16K | 682.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.97 | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 | -0.00 | -184.81 | 1421.16 |
| EPS Growth % | -183.07% | 50.27% | -580.72% | 71.08% | 78.19% | -2824.44% | - | 100% | -113% | - |
| EPS (Basic) | - | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 | -0.00 | -184.81 | 1421.16 |
| Diluted Shares Outstanding | 6.03M | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M | 10.78M | 1.86K | 1.86K |
| Basic Shares Outstanding | 6.03M | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M | 10.78M | 1.86K | 1.86K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As reported in recent financial filings, Coeptis Therapeutics exhibits highly erratic revenue patterns, with quarterly figures fluctuating from zero to $862K, suggesting that current top-line growth is driven by non-recurring milestone events rather than a stable, repeatable commercial product pipeline or consistent market demand.
The lack of consistent revenue generation highlights the company's status as a pre-commercial entity heavily reliant on project-based inflows. Investors should monitor whether future revenue streams can transition from these sporadic milestones to a more predictable licensing or product-based model.
Based on the provided income statement data, Coeptis maintains a rigid cost structure where SG&A expenses frequently exceed $2M per quarter, significantly dwarfing the company's limited revenue and indicating that operational discipline remains secondary to the aggressive pursuit of clinical development milestones.
The persistent high level of SG&A relative to revenue suggests that the company is carrying substantial administrative and infrastructure costs before achieving commercial scale. This cost profile appears unsustainable without a significant increase in revenue or a major reduction in non-essential operating expenditures.
According to the income statement, Coeptis frequently utilizes stock-based compensation, reaching as high as $1.4M in 2026Q1, which complicates the assessment of true operational losses and suggests that equity dilution is a primary mechanism for managing the company's ongoing cash requirements.
The reliance on stock-based compensation as a significant component of the cost structure warrants caution, as it obscures the true cash-burn dynamics of the business. Analysts should adjust for these non-cash items to better understand the underlying operational deficit and the potential for future shareholder dilution.
With operating margins consistently deep in negative territory, such as the -956% observed in recent periods, the company's reported cash position of $5.67M appears critically insufficient to support the long-term clinical development of the GEAR platform without immediate and potentially dilutive external financing.
The extreme disparity between current cash reserves and the ongoing burn rate suggests that the company is in a precarious financial position. This vulnerability may force management into unfavorable financing terms, which could significantly impair long-term shareholder value if clinical progress does not accelerate rapidly.
Quick answers to the most common questions about buying COEP stock.
For fiscal year 2025, Coeptis Therapeutics, Inc. (COEP) reported total revenue of $1.4M.
Coeptis Therapeutics, Inc. (COEP) reported a net loss of $11.9M for the fiscal year ending 2025.
Coeptis Therapeutics, Inc. (COEP) reported an operating income of $-13.0M, resulting in an operating profit margin of -956.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Coeptis Therapeutics, Inc. (COEP) generated $1.2M in gross profit for the year, representing a gross profit margin of 86.7%. This demonstrates the company's core pricing power and production efficiency.